Skip to content

The Neuromuscular Effect of Rocuronium in Patient

The Neuromuscular Effect of Rocuronium in Patient Measuring Muscle Mass by Bioelectrical Impedance Analysis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02657187
Enrollment
80
Registered
2016-01-15
Start date
2016-02-29
Completion date
2016-08-31
Last updated
2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass.

Detailed description

Rocuronium block neuromuscular transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. There have been several studies reported positive relationship between muscle mass and amount of neuromuscular junction. Until now, dose of rocuronium has been judged by patient's weight and height. When the rocuronium was developed, 50% effective dose and 95% effective dose of rocuronium was calculated by patient corrected body weight which used weight and height. However, height and weight do not represent exact muscle mass. The purpose of this study is to find 50% effective dose and 95% effective dose of rocuronium according to muscle mass. Measurement of muscle mass will be obtained using bioelectrical impedence analysis.

Interventions

DEVICEInbody

Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.

DRUGRocuronium

The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))

Sponsors

Go Eun Bae
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* All patient who undergo general anesthesia

Exclusion criteria

* Liver and kidney disease * Any types of muscle disorder. * Metal materials or pacemaker in body

Design outcomes

Primary

MeasureTime frameDescription
percentage of neuromuscular blockten minutespercentage of neuromuscular block is calculated by ratio of T1 to T4. T1 is result of first stimulation and T4 is result of fourth stimulation which are obtained by commonly used neuromuscular monitoring device.

Secondary

MeasureTime frameDescription
onset timeten minutestime from the end of injection of rocuronium until the maximal depression of T1 which is result of first twitch

Other

MeasureTime frameDescription
lag timeten minutestime from the end of injection of rocuronium until the first depression of the twitch response

Countries

South Korea

Contacts

Primary ContactGo eun Bae, M.D.
bgecs@naver.com821047265594

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026